N04BA02 • levodopa + benserazide • Nervous system | Dopaminergic agents | Dopa and dopa derivatives
Levodopa + Benserazide is a combination medication used in the treatment of Parkinson's disease and parkinsonian syndromes. Levodopa is a precursor of dopamine, which helps compensate for the dopamine deficiency in the brain characteristic of these conditions. Benserazide is a peripheral decarboxylase inhibitor that prevents levodopa from being converted into dopamine outside the brain, thereby increasing the treatment's effectiveness and reducing side effects.
This combination helps alleviate symptoms such as tremors, muscle rigidity, bradykinesia (slowness of movement), and balance difficulties. It is important to take the medication as prescribed by a doctor, with the dosage gradually adjusted to minimize side effects.
Side effects may include nausea, vomiting, dizziness, drowsiness, or motor fluctuations (such as 'on-off' phenomena). In rare cases, hallucinations or mood changes may occur. Regular medical monitoring is essential to adjust the treatment based on the progression of the disease.
Substance: levodopa + benserazide
Date of last drug list: 01-07-2013
Commercial code: W54607004
Concentration: 200mg / 50mg
Pharmaceutical form: tablets
Quantity: 60
Product type: generic
Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.